Evidence map›Paper›PMID 41226299›Full record

ArticleInternational journal of molecular sciences2025

Ergothioneine Attenuates Oxaliplatin-Induced Peripheral Neuropathy Without Compromising Antitumor Efficacy.

Takumu Yamada, Takumi Iwasawa, Ryohma Tsuchiya, Tomoaki Ito, Kazunori Kato

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takumu YamadaDepartment of Biomedical Engineering, Graduate School of Science and Engineering, Toyo University, Saitama 350-8585, Japan.
Takumi IwasawaInstitution of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.ORCID 0009-0008-9278-6464
Ryohma TsuchiyaShizuoka Medical Research Center for Disaster, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan.
Tomoaki ItoShizuoka Medical Research Center for Disaster, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan.ORCID 0000-0003-4190-8923
Kazunori KatoDepartment of Biomedical Engineering, Graduate School of Science and Engineering, Toyo University, Saitama 350-8585, Japan.

Funding

JSPS KAKENHI 23K24189
6 · The paper itself

Abstract

Colorectal cancer remains one of the leading causes of cancer-related mortality both in Japan and worldwide. Oxaliplatin (L-OHP) is a key chemotherapeutic agent used in the treatment of colorectal and other malignancies; however, its clinical use is often limited by the development of oxaliplatin-induced peripheral neuropathy (OIPN). In this study, we investigated ergothioneine (EGT), a natural antioxidant abundant in mushrooms, for its potential to mitigate OIPN without compromising the antitumor efficacy of L-OHP. Using the SH-SY5Y neuroblastoma cell line and differentiated neurons, we assessed the effects of EGT on L-OHP-induced apoptosis, oxidative stress, and axonal degeneration. We further evaluated whether EGT interferes with the anticancer activity of L-OHP using cultured cancer cell lines and a tumor-bearing mouse model. EGT suppressed L-OHP-induced apoptosis in neuronal cells and preserved axonal structures in differentiated neurons. Importantly, EGT had no adverse effect on the antitumor efficacy of L-OHP, as evidenced by unchanged cancer cell proliferation, tumor volume, and body weight in treated mice. These findings suggest that EGT may be a promising adjuvant for preventing OIPN while maintaining the therapeutic benefits of L-OHP.

Indexed as

Antineoplastic AgentsErgothioneineOxaliplatinPeripheral Nervous System DiseasesAnimalsAntioxidantsApoptosisCell Line, TumorCell ProliferationColorectal NeoplasmsHumansMaleMiceNeuronsOxidative StressXenograft Model Antitumor AssaysAntineoplastic AgentsAntioxidantsErgothioneineOxaliplatincolorectal cancerergothioneineoxaliplatinoxaliplatin-induced peripheral neuropathy (OIPN)

Identifiers

PMID41226299
PMCPMC12610496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.